胺碘酮联合普伐他汀治疗非瓣膜性阵发性心房颤动的疗效观察

Effect of Amiodarone combined with Pravastatin on Treatment of Non-valvular Paroxysmal Atrial Fibrillation

目的:探讨胺碘酮联合普伐他汀治疗非瓣膜性阵发性心房颤动(房颤)的临床疗效。方法:将2018年4月至2020年4月在广东省佛山市中医院禅城高新区医院诊治的非瓣膜性阵发性房颤患者100例随机均分为对照组和试验组各50例。对照组接受胺碘酮治疗,试验组在对照组基础上联合普伐他汀治疗,比较两组治疗效果。结果:治疗后试验组总有效率明显高于对照组(98.0%vs.80.0%,P<0.05);试验组房颤平均持续时间(67.67±3.32)min/月及发作次数(1.25±0.16)次/月均明显低于对照组的(73.23±5.93)min/月及(2.81±0.21)次/月(P均<0.05);治疗后试验组患者的TC(3.37±0.30)mmol/L、TG(1.76±0.17)mmol/L、LDL-C(1.39±0.29)mmol/L及hs-CRP(8.28±0.55)mg/L均明显低于对照组的(6.16±0.49)mmol/L、(2.17±0.26)mmol/L、(3.10±0.48)mmol/L及(19.98±2.76)mg/L(P均<0.05);治疗后试验组HDL-C明显高于对照组[(1.62±0.25)mmol/L vs.(1.50±0.24)mmol/L,P<0.05];对照组治疗前后TC、TG、LDL-C、HDL-C值无显著差异(P均>0.05)。结论:非瓣膜性阵发性房颤患者应用胺碘酮联合普伐他汀治疗效果显著。

Objective:To explore the efficacy of amiodarone combined with pravastatin on the treatment of non-valvular paroxysmal atrial fibrillation.Methods:100 patients with non-valvular paroxysmal atrial fibrillation were divided into two groups according to the random number table method in our hospital from Apr 2018 to Apr 2020,and each group was 50 cases.Control group was received amiodarone treatment only,while the experimental group was combined with pravastatin treatment for six monthes.The treatment effects were compared between the two groups.Results:After treatment,the total effective rate in the experimental group was significantly higher than that in the control group(98.0%vs80.0%,P<0.05).The average duration of atrial fibrillation in the experimental group was(67.67±3.32)min/monthly and monthly episodes(1.25±0.16)times were significantly lower than those in the control group(73.23±5.93)min/month and(2.81±0.21)times,both P<0.05.The serum levels of TC,TG,LDL-C and hs-CRP in the experimental group after treatment were significantly lower than those in the control group[(3.37±0.30)mmol/L vs(6.16±0.49)mmol/L,(1.76±0.17)mmol/L vs(2.17±0.26)mmol/L,(1.39±0.29)mmol/L vs(3.10±0.48)mmol/L and(8.28±0.55)mg/L vs(19.98±2.76)mg/L]respectively,all P<0.05.After treatment,the HDL-C in the experiment group was significantly higher than that in the control group[(1.62±0.25)mmol/L vs(1.50±0.24)mmol/L,P<0.05].The TC,TG,LDL-C,and HDL-C values in the control group was not statistically significant(P>0.05)before and after treatment.Conclusion:The treatment effect of amiodarone combined with pravastatin on patients with nonvalvular paroxysmal atrial fibrillation is better.